Which has higher valuation and earnings, RXST or CERS?

Cerus has higher revenue and earnings than RxSight. Cerus is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RxSight $134.48M 1.40 -$38.94M -$1.13 N/A Cerus $206.13M 2.19 -$15.63M -$0.03 N/A

Is RXST or CERS more profitable?

Cerus has a net margin of -3.06% compared to RxSight's net margin of -36.80%. Cerus' return on equity of -10.19% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.80% -17.35% -14.70% Cerus -3.06% -10.19% -3.14%

Does the media favor RXST or CERS?

In the previous week, Cerus had 1 more articles in the media than RxSight. MarketBeat recorded 3 mentions for Cerus and 2 mentions for RxSight. Cerus' average media sentiment score of 1.43 beat RxSight's score of 0.61 indicating that Cerus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cerus 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, EMBC or RXST?

Embecta has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Embecta $1.08B 0.32 $95.40M $1.48 4.18 RxSight $134.48M 1.40 -$38.94M -$1.13 N/A

Is EMBC or RXST more profitable?

Embecta has a net margin of 8.59% compared to RxSight's net margin of -36.80%. RxSight's return on equity of -17.35% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Embecta 8.59% -19.25% 10.82% RxSight -36.80% -17.35% -14.70%

Is RXST or SMTI more profitable?

Sanara MedTech has a net margin of -29.15% compared to RxSight's net margin of -36.80%. Sanara MedTech's return on equity of 29.72% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.80% -17.35% -14.70% Sanara MedTech -29.15% 29.72% 2.84%

Do analysts rate ACU or RXST?

RxSight has a consensus target price of $8.17, indicating a potential upside of 80.80%. Given RxSight's higher probable upside, analysts clearly believe RxSight is more favorable than Acme United. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acme United 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 RxSight 3 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.92

Which has higher earnings and valuation, ACU or RXST?

Acme United has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Acme United, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acme United $211.60M 1.11 $17.79M $2.38 25.79 RxSight $134.48M 1.40 -$38.94M -$1.13 N/A

Is ACU or RXST more profitable?

Acme United has a net margin of 10.25% compared to RxSight's net margin of -36.80%. Acme United's return on equity of 9.70% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets Acme United 10.25% 9.70% 6.10% RxSight -36.80% -17.35% -14.70%

RxSight (RXST) Competitors

$4.52 -0.01 (-0.22%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$4.65 +0.13 (+2.88%)

As of 04:44 AM Eastern

Compare

RXST vs. CERS, EMBC, SMTI, OSUR, and ACU

Should you buy RxSight stock or one of its competitors? RxSight's main competitors and comparable companies include Cerus (CERS), Embecta (EMBC), Sanara MedTech (SMTI), OraSure Technologies (OSUR), and Acme United (ACU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does RxSight compare to Cerus?

RxSight (NASDAQ:RXST) and Cerus (NASDAQ:CERS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

RxSight currently has a consensus target price of $8.17, suggesting a potential upside of 80.80%. Cerus has a consensus target price of $5.25, suggesting a potential upside of 134.38%. Given Cerus' stronger consensus rating and higher probable upside, analysts plainly believe Cerus is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

RxSight has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Cerus has a beta of 1.83, meaning that its stock price is 83% more volatile than the broader market.

In the previous week, Cerus had 1 more articles in the media than RxSight. MarketBeat recorded 3 mentions for Cerus and 2 mentions for RxSight. Cerus' average media sentiment score of 1.43 beat RxSight's score of 0.61 indicating that Cerus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cerus	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cerus has higher revenue and earnings than RxSight. Cerus is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	1.40	-$38.94M	-$1.13	N/A
Cerus	$206.13M	2.19	-$15.63M	-$0.03	N/A

78.8% of RxSight shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 10.1% of RxSight shares are held by company insiders. Comparatively, 5.3% of Cerus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cerus has a net margin of -3.06% compared to RxSight's net margin of -36.80%. Cerus' return on equity of -10.19% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.80%	-17.35%	-14.70%
Cerus	-3.06%	-10.19%	-3.14%

Summary

Cerus beats RxSight on 13 of the 16 factors compared between the two stocks.

How does RxSight compare to Embecta?

Embecta (NASDAQ:EMBC) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Embecta has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, RxSight has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

93.8% of Embecta shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 1.3% of Embecta shares are held by insiders. Comparatively, 10.1% of RxSight shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, RxSight had 1 more articles in the media than Embecta. MarketBeat recorded 2 mentions for RxSight and 1 mentions for Embecta. Embecta's average media sentiment score of 1.82 beat RxSight's score of 0.61 indicating that Embecta is being referred to more favorably in the media.

Company	Overall Sentiment
Embecta	Very Positive
RxSight	Positive

Embecta presently has a consensus price target of $11.00, suggesting a potential upside of 77.99%. RxSight has a consensus price target of $8.17, suggesting a potential upside of 80.80%. Given RxSight's stronger consensus rating and higher possible upside, analysts clearly believe RxSight is more favorable than Embecta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

Embecta has a net margin of 8.59% compared to RxSight's net margin of -36.80%. RxSight's return on equity of -17.35% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	8.59%	-19.25%	10.82%
RxSight	-36.80%	-17.35%	-14.70%

Embecta has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.32	$95.40M	$1.48	4.18
RxSight	$134.48M	1.40	-$38.94M	-$1.13	N/A

Summary

Embecta and RxSight tied by winning 8 of the 16 factors compared between the two stocks.

How does RxSight compare to Sanara MedTech?

RxSight (NASDAQ:RXST) and Sanara MedTech (NASDAQ:SMTI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

78.8% of RxSight shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 10.1% of RxSight shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Sanara MedTech has a net margin of -29.15% compared to RxSight's net margin of -36.80%. Sanara MedTech's return on equity of 29.72% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.80%	-17.35%	-14.70%
Sanara MedTech	-29.15%	29.72%	2.84%

RxSight has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

RxSight currently has a consensus price target of $8.17, suggesting a potential upside of 80.80%. Sanara MedTech has a consensus price target of $35.00, suggesting a potential downside of 0.34%. Given RxSight's stronger consensus rating and higher possible upside, analysts plainly believe RxSight is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Sanara MedTech has lower revenue, but higher earnings than RxSight. Sanara MedTech is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	1.40	-$38.94M	-$1.13	N/A
Sanara MedTech	$103.12M	3.13	-$37.56M	-$3.59	N/A

In the previous week, RxSight had 1 more articles in the media than Sanara MedTech. MarketBeat recorded 2 mentions for RxSight and 1 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.79 beat RxSight's score of 0.61 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company	Overall Sentiment
RxSight	Positive
Sanara MedTech	Very Positive

Summary

Sanara MedTech beats RxSight on 9 of the 16 factors compared between the two stocks.

How does RxSight compare to OraSure Technologies?

OraSure Technologies (NASDAQ:OSUR) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

OraSure Technologies has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, RxSight has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

RxSight has a net margin of -36.80% compared to OraSure Technologies' net margin of -43.70%. RxSight's return on equity of -17.35% beat OraSure Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OraSure Technologies	-43.70%	-19.09%	-16.26%
RxSight	-36.80%	-17.35%	-14.70%

OraSure Technologies presently has a consensus target price of $3.00, indicating a potential downside of 19.14%. RxSight has a consensus target price of $8.17, indicating a potential upside of 80.80%. Given RxSight's stronger consensus rating and higher probable upside, analysts clearly believe RxSight is more favorable than OraSure Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OraSure Technologies	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

RxSight has higher revenue and earnings than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OraSure Technologies	$115.02M	2.22	-$68.73M	-$0.69	N/A
RxSight	$134.48M	1.40	-$38.94M	-$1.13	N/A

93.5% of OraSure Technologies shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 4.7% of OraSure Technologies shares are owned by company insiders. Comparatively, 10.1% of RxSight shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, RxSight had 1 more articles in the media than OraSure Technologies. MarketBeat recorded 2 mentions for RxSight and 1 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 0.93 beat RxSight's score of 0.61 indicating that OraSure Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
OraSure Technologies	Positive
RxSight	Positive

Summary

RxSight beats OraSure Technologies on 12 of the 16 factors compared between the two stocks.

How does RxSight compare to Acme United?

Acme United (NYSE:ACU) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

RxSight has a consensus target price of $8.17, indicating a potential upside of 80.80%. Given RxSight's higher probable upside, analysts clearly believe RxSight is more favorable than Acme United.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acme United	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

Acme United has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, RxSight has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

Acme United has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Acme United, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acme United	$211.60M	1.11	$17.79M	$2.38	25.79
RxSight	$134.48M	1.40	-$38.94M	-$1.13	N/A

Acme United has a net margin of 10.25% compared to RxSight's net margin of -36.80%. Acme United's return on equity of 9.70% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acme United	10.25%	9.70%	6.10%
RxSight	-36.80%	-17.35%	-14.70%

In the previous week, RxSight had 2 more articles in the media than Acme United. MarketBeat recorded 2 mentions for RxSight and 0 mentions for Acme United. RxSight's average media sentiment score of 0.61 beat Acme United's score of 0.00 indicating that RxSight is being referred to more favorably in the news media.

Company	Overall Sentiment
Acme United	Neutral
RxSight	Positive

62.1% of Acme United shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 29.5% of Acme United shares are held by insiders. Comparatively, 10.1% of RxSight shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Acme United beats RxSight on 10 of the 17 factors compared between the two stocks.

Get RxSight News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RXST vs. The Competition

Export

Metric	RxSight	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$188.42M	$5.59B	$7.19B	$13.18B
Dividend Yield	N/A	1.74%	2.52%	19.60%
P/E Ratio	-4.00	20.94	221.68	20.80
Price / Sales	1.40	64.88	546.08	66.79
Price / Cash	N/A	32.11	76.68	52.75
Price / Book	0.67	5.72	10.41	5.92
Net Income	-$38.94M	$146.93M	$3.50B	$380.90M
7 Day Performance	-6.80%	-1.60%	-3.49%	-3.90%
1 Month Performance	-19.57%	-4.37%	-7.76%	-6.42%
1 Year Performance	-42.78%	0.70%	0.83%	-6.02%

RxSight Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RXST RxSight	2.4724 of 5 stars	$4.52 -0.2%	$8.17 +80.8%	-41.6%	$188.42M	$134.48M	N/A	461
CERS Cerus	2.3695 of 5 stars	$2.36 +0.6%	$5.25 +122.9%	+41.8%	$474.58M	$206.13M	N/A	345	News Coverage
EMBC Embecta	4.0079 of 5 stars	$6.04 +2.6%	$11.00 +82.3%	-54.3%	$341.04M	$1.08B	4.07	1,850	News Coverage Positive News
SMTI Sanara MedTech	0.8016 of 5 stars	$34.99 0.0%	$35.00 +0.0%	+17.2%	$321.48M	$109.81M	N/A	108
OSUR OraSure Technologies	1.6434 of 5 stars	$3.89 -5.5%	$3.00 -22.8%	+21.6%	$267.95M	$112.41M	N/A	500	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RXST) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RxSight (RXST) Competitors